New State Recovery Attack on RC4

This study investigates the pharmacokinetic (PK) and pharmacodynamic (PD) consequences of shifting from Quetiapine fumarate immediate-release (IR) to extended-release (XR) formulation in non-adherent schizophrenia patients. Monte-Carlo simulations using population PK and PD models were implemented to predict the time course of plasma concentration and Brief Psychiatric Rating Scale (BPRS) scores following the oral administration of 200 mg Seroquel® every 12 h and 400 mg Seroquel XR® every 24 h in patients experiencing dose delay, omission or doubling. Parameters were computed and their distributions were compared using the Kolmogorov–Smirnov test. Dose irregularities with both formulations had different effects on plasma concentration and %reduction in BPRS scores from baseline. However, the odds ratio of getting a %reduction in BPRS below 14%, or plasma concentration exceeding 500 µg/L, were comparable for adherent and non-adherent patients. Plasma therapeutic concentration after treatment cessation was maintained for <24 h in 48% and 29.6% of patients, and a steady state recovery time of <48 h was achieved in 51% and 13.4% of patients on the IR and XR formulations, respectively. Monte-Carlo simulations predict that the risks associated with the IR dose irregularities are not worsened when the XR formulation is used instead. Non-adherence events involving a single dose of either formulation do not require rescue doses.

Download Full-text

Solvent dependence of the ultrafast ground state recovery dynamics of phenol blue

Journal of Molecular Liquids ◽

10.1016/s0167-7322(01)00133-7 ◽

2001 ◽

Vol 90 (1-3) ◽

pp. 295-302 ◽

Cited By ~ 2

Author(s):

Yutaka Nagasawa ◽

Ayako Watanabe ◽

Yoshito Ando ◽

Tadashi Okada

Keyword(s):

Ground State ◽

State Recovery ◽

Solvent Dependence ◽

Phenol Blue ◽

Recovery Dynamics

Download Full-text

Generic Internal State Recovery on Strengthened HMAC: n-bit Secure HMAC Requires Key in All Blocks

IEICE Transactions on Fundamentals of Electronics Communications and Computer Sciences ◽

10.1587/transfun.e99.a.22 ◽

2016 ◽

Vol E99.A (1) ◽

pp. 22-30 ◽

Cited By ~ 1

Author(s):

Yu SASAKI ◽

Lei WANG

Keyword(s):

Internal State ◽

State Recovery

Download Full-text

The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’

Neurology neuropsychiatry Psychosomatics ◽

10.14412/2074-2711-2021-1-57-66 ◽

2021 ◽

Vol 13 (1) ◽

pp. 57-66

Author(s):

V. V. Kovalchuk

Keyword(s):

Emotional Disorders ◽

Clinical Manifestations ◽

Cerebrovascular Diseases ◽

Recent Experience ◽

Treatment And Prevention ◽

State Recovery ◽

Group 2 ◽

State Examination ◽

Group 1

COVID-19 worsens the course of cerebrovascular diseases (CVD), including chronic cerebral ischaemia (CCI). The Actovegin drug, which has long been widely used in CCI treatment, has an antioxidant and endothelium protective effect. It makes sense to study the effect of Actovegin therapy on the clinical manifestations of CCI in patients with a recent experience of COVID-19.Objective: to evaluate Actovegin efficacy in the treatment of CCI in patients with a recent experience of COVID-19.Patients and methods. The study included 440 patients (234 female; 206 male) with a recent experience of COVID-19, suffering from CCI, their average age being 67.8 years (from 54 to 85 years). All patients were broken down into two groups of 220 people (the patients in Group 1 were administrated Actovegin, the ones in Group 2 – were not). All patients were followed up for 90 days; their condition was assessed by the severity of clinical manifestations of CCI, using special scales and questionnaires.Results and discussion. After 90 days of follow-up, the frequency of complaints of cognitive impairment, sleep disorder, dizziness, fatigue, emotional disorders, and headache in Group 1 was significantly lower than in Group 2 (p<0.05). According to Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), Multidimensional Fatigue Inventory (MFI-20), and Spiegel Sleep Questionnaire (SSQ), the average indicators improved significantly more in Group 1 than in Group 2 (p<0.05). The absence of quality of life impairment and their minimal severity were observed in Group 1 in 77.9%; in Group 2 – in 33.7% (p<0.001). Statistically significant differences between the groups of patients were also observed in relation to emotional state recovery according to the Wakefield Questionnaire and the Spielberger State Trait Anxiety inventory.Conclusion. The observational study demonstrated the efficacy of Actovegin in the treatment of main clinical manifestations of CCI in patients with recent COVID-19 experience.

Download Full-text